@article {Hern{\'a}ndez-Ter{\'a}n2021.12.07.21267419, author = {Alejandra Hern{\'a}ndez-Ter{\'a}n and Angel E. Vega-S{\'a}nchez and Fidencio Mej{\'\i}a-Nepomuceno and Ricardo Serna-Mu{\~n}oz and Sebasti{\'a}n Rodr{\'\i}guez-Llamazares and Iv{\'a}n Salido-Guadarrama and Jose A. Romero-Espinoza and Cristobal Guadarrama-P{\'e}rez and JL Sandoval and Fernando Campos and Erika N. Mondrag{\'o}n-Rivero and Alejandra Ram{\'\i}rez-Venegas and Manuel Castillejos-L{\'o}pez and Norma A. T{\'e}llez-Navarrete and Christopher E. Ormsby and Rogelio P{\'e}rez- Padilla and Joel A. V{\'a}zquez-P{\'e}rez}, title = {Microbiota composition in the lower respiratory tract is associated with severity in patients with acute respiratory distress by influenza}, elocation-id = {2021.12.07.21267419}, year = {2021}, doi = {10.1101/2021.12.07.21267419}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Several factors are associated with the severity of the respiratory disease caused by the influenza virus. Although viral factors are one of the most studied, in recent years the role of the microbiota and co-infections in severe and fatal outcomes has been recognized. However, most of the work has focused on the microbiota of the upper respiratory tract (URT), hindering potential insights from the lower respiratory tract (LRT) that may help to understand the role of the microbiota in Influenza disease. In this work, we characterized the microbiota of the LRT of patients with Influenza A using 16S rRNA sequencing. We tested if patients with different outcomes (deceased/recovered), use of antibiotics, and different days of symptoms onset differ in their microbial community composition. We found striking differences in the diversity and composition of the microbiota depending on the days of symptoms onset and with mortality of the studied patients. We detected a high abundance of opportunistic pathogens such as Enterococcus, Granulicatella, and Staphylococcus in patients either deceased or with antibiotic treatment. Also, we found that antibiotic treatment deeply perturbs the microbial communities in the LRT and affect the probability of survival in Influenza A patients. Altogether, the loss of microbial diversity could, in turn, generate a disequilibrium in the community, potentially compromising the immune response increasing viral infectivity, promoting the growth of potentially pathogenic bacteria that, together with altered biochemical parameters, can be leading to severe forms of the disease. Overall, the present study gives one of the first characterizations of the diversity and composition of microbial communities in the LRT of Influenza patients and its relationship with clinical variables and disease severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financially supported by Consejo Nacional de Ciencia y Tecnologia (CONACyT) (Grant "Caracterizacion de la diversidad viral y bacteriana" to JAVP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Science, Biosecurity and Bioethics Committee of the Instituto Nacional de Enfermedades Respiratorias (protocol number B0615) and the patients or their legal guardians gave their written consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available Raw data at the NCBI Sequence Read Archive (SRA)(PRJNA770291).}, URL = {https://www.medrxiv.org/content/early/2021/12/08/2021.12.07.21267419}, eprint = {https://www.medrxiv.org/content/early/2021/12/08/2021.12.07.21267419.full.pdf}, journal = {medRxiv} }